NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Tyra Biosciences, Inc. (TYRA) Stock Analysis

Tyra Biosciences, Inc. (TYRA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

TYRA

$20.60

+$0.13 (+0.64%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TYRA with… →

TYRA Key Statistics

As of Oct 21, 2026
Trading
Open
$20.52
Previous Close
$20.47
Day's Range
20.13–20.99
52-Week Range
13.35–40.65
Volume
724.32K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.75
Valuation
Market Cap
$1.42B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.39
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$119.95M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
68.76M
1-Year Return
+40.04%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
861.04K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, TYRA closed at $20.60, +40.04% over 1 year.

Tyra Biosciences, Inc. (TYRA) has a market capitalization of $1.42B.

In fiscal 2025, TYRA reported revenue of $0.00.

TYRA Stock Return by Calendar Year

Tyra Biosciences, Inc. (TYRA) return since Sep 2021: what $10,000 became

1 year
$10,000 $14,004
+40.04%
5 years
$10,000 $9,595
−4.05%
Since Sep 2021
$10,000 $7,923
−20.77%

If you had invested $10,000 in Tyra Biosciences, Inc. (TYRA) at the close on September 15, 2021, the earliest close on record here, it would have been worth $7,923 at the close on October 21, 2026: −20.77% in total, −4.46% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−21.64%
2025+89.14%
2024+0.36%
2023+82.24%
2022−45.98%
2021 (partial year)−45.88%

As of October 21, 2026.

TYRA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$119.95M—
2024$0.00−$86.48M—
2023$0.00−$69.13M—
2022$0.00−$55.33M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$132.76M−$119.95M—
2024$0.00—−$104.18M−$86.48M—
2023$0.00—−$79.95M−$69.13M—
2022$0.00—−$58.93M−$55.33M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Tyra Biosciences, Inc. (TYRA) is capitalised at $1.42B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 87.

The most recent close on file for TYRA is $20.60, dated October 21, 2026. That is +$0.13 (+0.64%) against the previous close. The 52-week range on file runs from $13.35 to $40.65. The latest close sits 54.31% above that 52-week low.

Financial Health

In fiscal 2025, Tyra Biosciences, Inc. reported revenue of $0.00. The same year closed with a net loss of $119.95M. Trailing earnings per share are −2.39.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Over the trailing twelve months the total return is +40.04%. Across 5 years the annualized return works out at −0.82%. Beta against the wider market is reported at 0.75. Daily returns over the trailing 5 years annualize to a volatility of 80.32%.

Growth & Income

The record shows no dividend for TYRA.

2026 is still running; the total return is −21.64% year to date. The strongest complete calendar year on file is 2025 at +89.14%; the weakest is 2022 at −45.98%. Of the 4 complete calendar years on file, 3 finished higher.

Peer Comparison

Tyra Biosciences, Inc. (TYRA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Tyra Biosciences, Inc. TYRA $1.42B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Tyra Biosciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Tyra Biosciences, Inc.

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.

Visit website →